Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
BACKGROUND
Enzyme replacement therapy (ERT) with alpha-galactosidase A (alpha-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry disease mouse model and compared it with that of ERT.


METHODS
A pseudotyped rAAV2/8 vector encoding alpha-Gal A cDNA (rAAV2/8-hAGA) was prepared and injected into 18-week-old male Fabry mice through the tail vein. The alpha-Gal A expression level and globotriaosylceramide (Gb3) levels in the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural studies were conducted.


RESULTS
Treatment of Fabry mice with rAAV2/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as liver, spleen, kidney, heart, and brain with concomitant elevation of alpha-Gal A enzyme activity. Enzyme activity was elevated for up to 60 weeks. In addition, expression of the alpha-Gal A protein was identified in the presence of rAAV2/8-hAGA at 6, 12, and 24 weeks after treatment. alpha-Gal A activity was significantly higher in the mice treated with rAAV2/8-hAGA than in Fabry mice that received ERT. Along with higher alpha-Gal A activity in the kidney of the Fabry mice treated with gene therapy, immunohistochemical studies showed more alpha-Gal A expression in the proximal tubules and glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The alpha-gal A gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT.


CONCLUSIONS
The rAAV2/8-hAGA mediated alpha-Gal A gene therapy provided improved efficiency over ERT in the Fabry disease mouse model. Furthermore, rAAV2/8-hAGA-mediated expression showed a greater effect in the kidney than ERT.
Choi
Jin-Ok
JO
Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158-710, Korea.
Lee
Mi Hee
MH
Park
Hae-Young
HY
Jung
Sung-Chul
SC
D000818:Animals; D000229:Dependovirus / Q000235:genetics* / Q000378:metabolism; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D014281:Trihexosylceramides / Q000235:genetics / Q000378:metabolism; D000519:alpha-Galactosidase / Q000235:genetics / Q000378:metabolism
D014281:Trihexosylceramides; C018549:globotriaosylceramide; D000519:alpha-Galactosidase
Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36
18431378
Hum Gene Ther. 1999 Jul 1;10(10):1667-82
10428212
Clin Microbiol Rev. 2008 Oct;21(4):583-93
18854481
J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S139-43
12068026
Annu Rev Med. 2006;57:283-96
16409150
Am J Kidney Dis. 2005 Jul;46(1):120-7
15983965
Hum Gene Ther. 1999 Aug 10;10(12):1931-9
10466627
FEBS Lett. 1997 Nov 3;417(1):89-91
9395081
Biochim Biophys Acta. 1998 Apr 28;1406(3):260-6
9630664
Clin Nephrol. 1997 Feb;47(2):71-5
9049452
Mol Ther. 2007 Mar;15(3):492-500
17191071
Mol Ther. 2004 Feb;9(2):231-40
14759807
N Engl J Med. 2001 Jul 5;345(1):9-16
11439963
J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S134-8
12068025
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2676-81
11226298
J Biol Chem. 1978 Jan 10;253(1):184-90
201618
Glycobiology. 2003 Apr;13(4):305-13
12626384
J Virol. 2000 Oct;74(20):9451-63
11000214
Biologics. 2008 Dec;2(4):823-43
19707461
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):365-70
10618424
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4
9122231
Indian J Pathol Microbiol. 1999 Jan;42(1):1-2
10420677
N Engl J Med. 1967 May 25;276(21):1163-7
6023233
Am J Hum Genet. 2001 Jan;68(1):14-25
11115376
Hum Gene Ther. 2009 Aug;20(8):796-806
19569968
Mol Ther. 2006 Jan;13(1):77-87
16219492
J Pediatr. 2004 May;144(5 Suppl):S20-6
15126980
JAMA. 2001 Jun 6;285(21):2743-9
11386930
J Am Soc Nephrol. 2007 May;18(5):1547-57
17409312
J Lipid Res. 1965 Jul;6:428-31
14336214
J Am Soc Nephrol. 2007 Mar;18(3):698-706
17287429
Annu Rev Biochem. 1991;60:257-80
1883197
Ann Neurol. 1992 Apr;31(4):409-15
1375013
J Am Soc Nephrol. 2007 Sep;18(9):2609-17
17656478
Medicine (Baltimore). 2002 Mar;81(2):122-38
11889412
J Virol. 2005 Jan;79(1):214-24
15596817